Skip to main content
. 2022 Apr 21;42(10):1319–1327. doi: 10.1038/s41372-022-01391-9

Fig. 1. Study design.

Fig. 1

Study design of patient cohorts for serum cytokine analysis. Control: mothers with no report of COVID-19 disease at any time during their pregnancy and negative for SARS-CoV-2 at time of delivery screening. Early COVID: mothers with SARS-CoV-2 positive testing within the 1st or 2nd trimester of pregnancy (1–27 weeks gestation). Late COVID: mothers with SARS-CoV-2 positive testing in the 3rd trimester of pregnancy (28–41 weeks gestation).